Reviewer's report

**Title:** Efficacy of Alogliptin in Type 2 Diabetes Treatment: A Meta-analysis on Randomized Double Blind Controlled Studies

**Version:** 3  **Date:** 30 January 2013

**Reviewer:** marc rendell

**Reviewer's report:**

The authors have now responded to my requests regarding the benefits of alogliptin in their metaanalysis population. They have acknowledged the potential differences in the Japanese cohorts.

They do not acknowledge skin issues with alogliptin. That is puzzling. Was their population too small?

They should definitely add that with wider use alogliptin has manifested events not raised in the meta-analysis, including pancreatitis and Stevens Johnson syndrome. It would make this paper much more interesting to discuss what low frequency events can be missed in a meta-analysis.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Needs some language corrections before being published

**Statistical review:** Yes, and I have assessed the statistics in my report.

**Declaration of competing interests:**

I have no competing interests